Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

NCT00417807 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Desmoplastic Small Round Cell Tumors

Interventions

DRUG: Imatinib mesilate

Sponsor

Novartis Pharmaceuticals